Hematobiochemical Alterations in Ctvt: Evaluating Systemic Effects of Scaffold-Based Chemotherapy

Canine Transmissible Venereal Tumor (CTVT) not only presents as a localized neoplastic condition but also influences systemic physiological parameters, particularly during chemotherapy. Monitoring hematological and biochemical changes is essential for evaluating the safety and effectiveness of treatment. Scaffold-based delivery of chemotherapeutic agents such as vincristine and cisplatin provides an opportunity to assess these systemic effects more precisely¹. 

Hematological Changes During Treatment 

Hemoglobin levels in dogs treated with vincristine scaffolds show a gradual but non-significant increase over the course of treatment. This rise may be attributed to the reduction in chronic blood loss from ulcerated tumor surfaces as the tumor regresses. Similar trends are observed in animals treated with cisplatin scaffolds, where hemoglobin levels increase slightly but remain within physiological limits ¹. 

Packed cell volume (PCV) values also remain relatively stable throughout the study period. Minor fluctuations are observed, but no significant differences are noted between different time intervals in either treatment group. These findings suggest that scaffold-based chemotherapy does not adversely affect erythropoiesis. 

Leukocyte and Differential Count Variations 

Total leukocyte count (TLC) demonstrates a significant decrease in animals treated with vincristine scaffolds. This reduction is observed consistently from the second week onward and may be associated with mild myelosuppression and suppression of the reticuloendothelial system¹. 

In animals treated with cisplatin scaffolds, TLC initially decreases and then shows a tendency to return toward baseline levels by the fourth week. This variation reflects a transient effect of chemotherapy on immune cell populations. Neutrophil counts do not show significant changes in either group, indicating that neutrophil dynamics remain relatively stable during treatment. 

Lymphocyte counts exhibit a different pattern, particularly in the vincristine-treated group, where a significant increase is observed over time. This lymphocytosis may be related to immune response mechanisms or compensatory changes following bone marrow suppression. In the cisplatin group, lymphocyte levels increase gradually but remain within non-significant limits¹. 

Serum Biochemical Parameters 

Serum protein levels show a slight decrease in both treatment groups, particularly by the fourth week. This decrease remains within normal physiological limits and may be associated with mild impairment in absorption or increased metabolic demand during tumor regression. Similar observations have been reported in previous studies^2,3. 

Serum albumin levels remain stable throughout the treatment period in both groups, indicating that neither vincristine nor cisplatin scaffolds exert significant adverse effects on hepatic function. Liver enzymes, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), also remain within normal limits, suggesting preservation of liver integrity^1,4. 

Renal Function and Drug Safety 

Renal parameters provide important insights into drug safety. In animals treated with vincristine scaffolds, blood urea nitrogen (BUN) and creatinine levels remain within normal physiological limits throughout the study. This indicates that vincristine, when delivered through scaffolds, does not significantly affect renal function. 

In contrast, animals treated with cisplatin scaffolds show a significant increase in BUN and creatinine levels over time. These changes suggest a degree of renal stress or impairment, highlighting the need for careful monitoring when using cisplatin-based therapies¹. 

Glucose Levels and Metabolic Changes 

Blood glucose levels remain largely unchanged in both treatment groups, with only minor fluctuations observed. In some cases, a slight decrease in glucose levels is noted, which may be attributed to increased utilization of glucose by tumor cells or alterations in metabolic processes¹. 

Conclusion 

Hematobiochemical evaluation in CTVT provides essential information regarding the systemic effects of chemotherapy. Vincristine scaffold therapy demonstrates a favorable safety profile with minimal impact on hematological and biochemical parameters. In contrast, cisplatin therapy requires closer monitoring due to its potential effects on renal function. Regular assessment of these parameters enables clinicians to ensure safe and effective management of CTVT while minimizing treatment-related complications. 

Reference: 

1. Kumar A, Jadon NS, Zaidi MG, Kandpal M, Saini R. Transmissible Venereal Granuloma Invasiveness and Response to Chemotherapeutics in Canine. Int. J. Contemp. Res. Multi.[Internet]. 2024;3(3):140-7. https://multiarticlesjournal.com/counter/d/3-3-58/IJCRM-2024-3-3-58.pdf 

2. Frampton D, Schwenzer H, Marino G, Butcher LM, Pollara G, Kriston-Vizi J, Venturini C, Austin R, de Castro KF, Ketteler R, Chain B. Molecular signatures of regression of the canine transmissible venereal tumor. Cancer cell. 2018 Apr 9;33(4):620-33. https://www.cell.com/cancer-cell/fulltext/S1535-6108(18)30071-0?sf186924969=1 

3. Ganguly B, Das U, Das AK. Canine transmissible venereal tumour: a review. Vet Comp Oncol. 2016;14:1-12. https://drive.google.com/file/d/1JAA2BdHoRo4bZ_V7wDn_quknNNNu_9pn/view 
4. Antonov A. Successful treatment of canine transmissible venereal tumor using vincristine sulfate. Adv Res. 2017;5(5):1-5. Article no.AIR.20017. ISSN: 2348-0394. https://www.researchgate.net/profile/Anton-Antonov-4/publication/282421949_Successful_Treatment_of_Canine_Transmissible_Venereal_Tumor_Using_Vincristine_Sulfate/links/5671620708ae0d8b0cc2f1c1/Successful-Treatment-of-Canine-Transmissible-Venereal-Tumor-Using-Vincristine-Sulfate.pdf